QIAGEN COVID-19 emergency protocols


Global efforts in the fight against COVID-19
A COVID-19 test for every situation

From the onset of the novel coronavirus outbreak, QIAGEN’s dedicated global teams have been working around the clock to ensure the availability of existing testing solutions and to develop new SARS-CoV-2 tests to address international testing needs.

Today, we offer a comprehensive portfolio of SARS-CoV-2 testing solutions on the market, covering the needs of clinical and research customers, from manual to automated sample processing, low to high throughput, single-plex to multi-plex, and from active infection testing to the detection of previous viral exposure.

Francesca DiPasquale, QIAGEN employee, mask, coronavirus
Avoiding repeat hospital visits with syndromic testing

The team at Mako Medical ensure fast test results to vulnerable senior communities, knowing that delays can present a real dilemma for patients with little time for diagnoses.

QIAstat-Dx, QIAstat-Dx analyzer, Mako, diagnostics, syndromic testing, instrument, cartridge, technician, lab tech, lab, laboratory, respiratory panel, customer story, hero story
Hospital floor, person with mask and protection suit, walking, unfixing the mask, two more people in the back, 06/2015, (General, Photography, Doctor/Physician, Hospital)
Diagnostic testing for COVID-19

We have developed a comprehensive portfolio of COVID-19 diagnostic testing solutions including targeted and multiplex PCR detection and rapid antigen and antibody tests. We also supports several testing protocols by providing test components and mid- to high-throughput automation solutions.

COVID-19 research solutions

Pandemics require accelerated development of innovative technologies to provide rapid and effective responses. QIAGEN supports scientists seeking to better understand the SARS-CoV-2 virus with research tools. Our portfolio includes a full spectrum of our high-performance NGS solutions and integrated bioinformatics pipelines that collectively drive a greater understanding of the multiple facets of SARS-CoV-2 biology.

people working in a laboratory, conversation, talk
Rapid response to coronavirus QIAGEN
Latest news on QIAGEN’s COVID-19 efforts

At QIAGEN we work tirelessly on novel approaches to support healthcare workers and scientists in their fight against COVID-19.

We have dramatically scaled up production, moving to 24 hour, seven-day-a-week operations at our manufacturing sites. Stay up-to-date with our latest developments here. 


How can we support your lab?

Reach a specialist about SARS-CoV-2 resources.
In the United States:
QIAreach SARS-CoV-2 Antigen testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, to perform high complexity tests.
The QIAreach SARS-CoV-2 Antigen Test has been validated but FDA's independent review of this validation is pending.
Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.